GlassScriptPhysician profile
Massanu A Sirleaf
NPI 1962725382
$3,492.65
in general payments reported to CMS, 2019-2025
30 companies · $790 in 2025
The $790 reported for 2025 was more than what 84% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $584 · 2023: $927 · 2024: $1,032 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $768.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.93 | 2022-2025 | Xifaxan, Trulance |
| Abbvie INC. | $312.15 | 2021-2025 | |
| Novo Nordisk INC | $308.17 | 2021-2025 | Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $253.68 | 2022-2024 | |
| Neurelis, INC. | $193.78 | 2022-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $178.72 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $156.76 | 2023-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $142.27 | 2022-2023 | |
| Lundbeck LLC | $117.43 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $90.47 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $83.66 | 2025 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.59 | 2021-2025 | Caplyta |
| Boston Scientific Corporation | $60.55 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Sanofi-Aventis U.S. LLC | $46.53 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.66 | 2025 | Cologuard Collection Kit |
| Depuy Synthes Sales INC. | $36.98 | 2024 | Orthovisc |
| Pulmonx Corporation | $30.72 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Tempus Ai, INC | $29.34 | 2024 | |
| Microtransponder, INC. | $25.24 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.47 | 2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $23.81 | 2023 | Verquvo, Steglatro, Belsomra |
| Grifols USA, LLC | $22.30 | 2024 | Prolastin-C Liquid |
| Neurocrine Biosciences, INC. | $21.81 | 2025 | |
| Abiomed | $21.79 | 2024 | Impella |
| Kyowa Kirin, INC. | $19.77 | 2023 | |
| Baxter Healthcare | $19.43 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Nevro Corp. | $18.01 | 2024 | Senza |
| Lucid Diagnostics INC. | $15.29 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $12.84 | 2023 | Prehevbrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Massanu Sirleaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.